AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04391764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo tablets will be identical in size, colour, shape, and taste and will be given in the similar manner.
Study NCT04543500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
Study NCT04543500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Real-time functional magnetic resonance neurofeedback (rtfMRI-nf)
Description: Real-time functional magnetic resonance imaging neurofeedback (rtfMRI-nf) is a procedure using an MRI scanner that allows participants to observe their own neural activity in the moment. They are taught to self-regulate this activity during a task.
Study NCT04884828 — intervention group
Intervention type: DEVICE
Intervention: external gas during NIV
Description: The procedure was performed in the patient's room during his or her hospital stay to avoid additional visits for study participation. The patient was placed in the supine position, and the usual ventilator interface was placed in a single-limb system, along with the commercial ventilator to be studied. The ventilator model were evaluated at bedside in random order. The parameters of the ventilator were the same as those that the patients used at home (that is, unlike the bench study, the sensitivity of the trigger was not modified). A external polygraph was used to moritor the study, with the incorporation of thoracic and abdominal bands and parasternal electromyography, to better evaluate asynchronies, in addition to pulse oximetry control. The ventilation periods were 1 minute (without gas, gas, without gas). This sequence was performed twice in each group of established conditions.
Study NCT04304677 — intervention group
Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: 1. Pre-PCI FFR pullback recording was done with conventional system~2. Automated algorithm to calculate delta FFR per unit time was developed~3. PCI was performed using 2nd generation DES
Study NCT03921112 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasound
Description: bedside lung ultrasound will be done for patients
Study NCT03921112 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine tools
Description: chest X-ray , ABG, RSBI, Ventilator parameters will be done for all patients
Study NCT01098695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecological Family Intervention and Treatment (EcoFIT)
Description: Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
Study NCT02986386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental occlusion restoration
Description: Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
Study NCT02986386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dental occlusion restoration
Description: Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
Study NCT02986386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment of malocclusion
Description: Orthodontic therapy to treat malocclusion
Study NCT02986386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Orthodontic treatment of malocclusion
Description: Orthodontic therapy to treat malocclusion
Study NCT06111170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression dressing
Description: Application of dressing
Study NCT04342559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Belamy (vaginal moisturizer)
Description: The conformity of the product use by the research participants will be verified through the filling of the product use diary by the research participants and also by the accounting of the tubes not used in T22.~Interdiction and Restriction~* Keep the test product tightly closed, protected from heat, moisture and out of the reach of children;~* Do not apply any other product to the genital area. Only the use of soap normally used for hygiene will be allowed;~* Do not change genital / vaginal hygiene habits;~* Not having sexual intercourse in the 48 hours (2 days) before the research visits;~* Do not perform a hygienic shower in the genital region within 24 hours (1 day) prior to the research visits;~* Do not perform gynecological / intimate showers during the study period
Study NCT00655590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 20 mg daily dosing
Study NCT00655590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: 100 mg daily dosing
Study NCT00655590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebos
Study NCT02331498 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pazopanib
Description: Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
Study NCT01551498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anatabloc Supplement
Description: Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
Study NCT01551498 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, as mint flavored lozenges, to be taken 3 times each day
Study NCT03194217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEN-2001
Description: Bavisant dihydrochloride monohydrate for oral use
Study NCT03194217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04017494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Magnetic Resonance Imaging
Description: Cardiac Magnetic Resonance Imaging (non-invasive, with i.v. application of contrast), awake or (if clinically indicated) in general anesthesia
Study NCT04017494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw for hematocrit and heart failure biomarkers
Description: Approximately 10 ml of blood will be drawn before administration of contrast medium.
Study NCT04017494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test
Description: In patients 8 years of age or older: on a cycle ergometer with breath-by-breath analysis, continuous ECG and SpO2 monitoring during exercise, after a baseline spirometry and bodyplethysmography
Study NCT04017494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Exhalomics
Description: Measurement of exhaled molecules by mass spectrometry; patients breathe into a mouthpiece for 15 seconds 6 times (total time requirement: about 5 minutes)
Study NCT04017494 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quality of life questionnaire
Description: Questionnaire to be filled out by the Patient regarding quality of life perception
Study NCT03829891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beinaglutide
Description: 1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )
Study NCT03829891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beinaglutide
Description: 1. Beinaglutide for 8 weeks,~2. Beinaglutide + glargine for 8 weeks(only the subjects whose blood glucose not reach the standard )
Study NCT03829891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine
Description: 1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )
Study NCT03829891 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: glargine
Description: 1. Glargine for 8 weeks,~2. Glargine+Beinaglutide for 8 weeks(only the subjects whose blood glucose not reach the standard )
Study NCT02004535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation
Description: The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
Study NCT02996591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block
Study NCT02996591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block
Study NCT01687803 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to \~60 min/day for 6 days/week (\~360 minutes per week).
Study NCT02996591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed
Study NCT01820260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ingenol mebutate gel
Study NCT01820260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02996591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 45-60 mg of 1.5% mepivacaine for spinal anesthesia
Study NCT02996591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia
Study NCT03324594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: (1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)
Description: 1. WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.~2. WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.~3. The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available.
Study NCT01370733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEST-1 (NeoSync EEG Synchronized TMS)
Description: The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
Study NCT01370733 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
Study NCT05383794 — intervention group
Intervention type: OTHER
Intervention: Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Description: Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.
Study NCT01687803 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
Study NCT01732783 — intervention group
Intervention type: OTHER
Intervention: Panitumumab + Chemotherapy
Description: Participants receiving panitumumab in combination with chemotherapy as prescribed by the treating physician prior to enrollment in this study and according to routine clinical practice for patients with wild-type RAS metastatic colorectal cancer.
Study NCT00845182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
Study NCT00845182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
Study NCT00075270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Active Comparator
Study NCT00075270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Active Comparator
Study NCT00075270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW572016 (Lapatinib)
Description: Oral GW572016 Lapatinib
Study NCT03361644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Participants assigned to HIIT will participate in treadmill exercise in intervals consisting of 1 minute intervals of challenging intensities with recovery periods in between, gradually increasing the number of intervals over the course of the study.
Study NCT03361644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-Intensity Continuous Training
Description: Participants assigned to CMIT will participate in constant moderate intensity treadmill exercise, gradually increasing the duration of the exercise over the course of the study.
Study NCT00767182 — intervention group
Intervention type: OTHER
Intervention: blood sample
Description: biological markers evaluated : D-Dimer, sEPCR
Study NCT04661098 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (Darwish hymenotomy technique)
Description: Formation of an annular hymen in cases of postpubertal imperforate hymen using a laparoscopic trocar (Darwish hymenotomy technique)
Study NCT00464243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volinanserin
Description: oral administration
Study NCT00464243 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT00159822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.~Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours
Study NCT00635024 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.5 mg/kg
Study NCT00635024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 16 mg/m\^2
Study NCT02727543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medisafe
Description: Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements
Study NCT04164693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Description: patients began to use low molecular weight heparin or warfarin sodium tablets.
Study NCT04164693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: non anticoagulant therapy group
Description: no anticoagulant was used after operation.
Study NCT04636853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP)
Description: A subretinal injection of umbilical cord blood platelet-rich plasma (CB-PRP) will be performed only in one eye, the other eye will be considered as a control group.~A complete morpho-functional ophthalmological evaluation will be performed in all patient at each control.
Study NCT01221740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savella
Description: The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.~12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8
Study NCT04329689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Septal myectom
Description: The Septal myectomy is the preferred treatment of most patients with HOCM, and many studies have documented relief of symptoms and satisfactory late patient survival after relief of outflow tract gradients.~valve repair or replacement may be necessary
Study NCT02755792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calligraphy Training
Study NCT02755792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iPad Training
Study NCT02728973 — intervention group
Intervention type: OTHER
Intervention: ERAS program
Description: The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
Study NCT00005866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
Study NCT00005866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
Study NCT00005866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: both arms per published schedule
Study NCT00005866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
Study NCT00005866 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: day 0
Study NCT00005866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: both arms: 1200 cGy total dose (6 x 200 fractions)
Study NCT02331160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rebozo
Description: Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
Study NCT03486314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Pevonedistat intravenous infusion.
Study NCT03486314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Rifampin capsules.
Study NCT03486314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel intravenous infusion.
Study NCT03486314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion.
Study NCT03486314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel intravenous infusion.
Study NCT05152355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 200 microgram/Puff, HFA MDI
Description: Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Study NCT05152355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 100 microgram/Actuation Powder for Inhalation
Description: Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Study NCT00930410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangio-Pancreatography (ERCP)
Description: Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
Study NCT02764879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acids
Description: omega3 received 2 times daily-for 6 months
Study NCT02764879 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: scaling and root planing
Study NCT02764879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scaling and root planing
Study NCT02764879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo soft gelatin capsules
Description: placebo soft gelatin capsules received 2 times daily-for 6 months
Study NCT03830281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultra-Rapid Lispro
Description: Administered SC
Study NCT03830281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study NCT04194177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mechanical ventilation during robotic surgery
Description: protective ventilation PEEP= 6 cmh2o TV= 6 ml/kg conventional PEEP=2 cmH2O and TV=9 ml/kg